The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway

(L597V)BRAF mutations are acquired somatically in human cancer samples and are frequently coincident with RAS mutations. Germline (L597V)BRAF mutations are also found in several autosomal dominant developmental conditions known as RASopathies, raising the important question of how the same mutation...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Główni autorzy: Andreadi, Catherine, Cheung, Lai-Kay, Giblett, Susan, Patel, Bipin, Jin, Hong, Mercer, Kathryn, Kamata, Tamihiro, Lee, Pearl, Williams, Alexander, McMahon, Martin, Marais, Richard, Pritchard, Catrin
Format: Artigo
Język:Inglês
Wydane: Cold Spring Harbor Laboratory Press 2012
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3435497/
https://ncbi.nlm.nih.gov/pubmed/22892241
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/gad.193458.112
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy